Originally published by our sister publication Infectious Disease Special Edition
The FDA does not expect tixagevimab co-packaged with cilgavimab (TIX+CIL) (Evusheld, AstraZeneca) to have the ability to neutralize XBB.1.5, a new emerging omicron subvariant, the agency said.
The CDC estimates XBB.1.5 to be responsible for nearly 30% of variant circulation in the United States.
In October, the FDA released an update adding important information to the authorized Fact Sheets for Evusheld to inform